Cubist Pharmaceuticals Announces Promotion of Steven C. Gilman, Ph.D., to EVP, Research and Development and Chief Scientific Off

Cubist Pharmaceuticals Announces Promotion of Steven C. Gilman, Ph.D., to EVP, Research and Development and Chief Scientific Officer
 
Company Release - 09/07/2010 13:02
 
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Steven C. Gilman, Ph.D., has been promoted to Executive Vice President, Research and Development and Chief Scientific Officer. Dr. Gilman joined Cubist in 2008 as Senior Vice President, Discovery and Non-clinical Development and Chief Scientific Officer.

Dr. Gilman has more than 25 years of drug research and development experience. Before joining Cubist, he was Chairman of the Board and Chief Executive Officer of ActivBiotics, Inc. While at ActivBiotics, Dr. Gilman led the transition of the organization from early research/academic stage to focus on advanced product development/commercialization. Previously he was Vice President and General Manager, Inflammation Franchise, Millennium Pharmaceuticals, Inc. Earlier in his career, Dr. Gilman was responsible for pharmaceutical research units at Pfizer, Sterling Winthrop, Cytogen Corporation and Wyeth Laboratories in areas including chronic inflammatory diseases, transplant rejection, autoimmune diseases and bacterial infections.

Dr. Gilman has a Ph.D. in Microbiology from Pennsylvania State University and completed his post doctoral training in the Department of Immunopathology at Scripps Clinic and Research Foundation in La Jolla, California.

Cubist President and CEO Michael Bonney said, "We have been fortunate to have had the benefit of Steve's scientific and business acumen for the last two and a half years as he has led our discovery and non-clinical development organization. Now he will apply his diverse management skills to a broader organization that encompasses our overall corporate pipeline strategy."

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program, added with Cubist's acquisition of Calixa Therapeutics Inc. in December 2009, focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea); and a Phase 1 program intended to address the unmet medical need for a treatment for serious infections caused by MDR Gram-negative pathogens. Cubist is also working on several pre-clinical programs being developed to address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist's web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.


Source: Cubist Pharmaceuticals, Inc.

Contact:
Cubist Pharmaceuticals, Inc.

Eileen C. McIntyre, 781-860-8533

Senior Director, Corporate Communications

[email protected]

or

Weber Shandwick

Tara Murphy, 617-520-7045

[email protected]
 


 

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.